Published in:
Open Access
01-11-2019 | Stroke | Original Paper
One year VARC-2-defined clinical outcomes after transcatheter aortic valve implantation with the SAPIEN 3
Authors:
Costanza Pellegrini, Tobias Rheude, Teresa Trenkwalder, N. Patrick Mayr, Michael Joner, Adnan Kastrati, Heribert Schunkert, Oliver Husser, Christian Hengstenberg
Published in:
Clinical Research in Cardiology
|
Issue 11/2019
Login to get access
Abstract
Aims
To evaluate 1-year outcome after transcatheter aortic valve implantation (TAVI) using the SAPIEN 3 (S3) prosthesis with emphasis on the composite endpoints “clinical efficacy after 30 days” and “time-related valve safety” proposed by the updated Valve Academic Research Consortium (VARC-2).
Methods and results
Four hundred and two consecutive patients undergoing transfemoral TAVI with the S3 were enrolled. Mean age was 81 ± 6 years, 43% were female and median logistic EuroSCORE I was 12% [8–19]. Device success was achieved in 93% (374/402) with moderate or severe paravalvular leakage (PVL) in 2%. At 1 year all-cause mortality was 8.9% [95% CI 6.4–12.2] and new permanent pacemaker implantation rate was 16% [95% CI 12.7–20.4]. The composite endpoint time-related valve safety occurred in 29% with structural valve deterioration, defined as elevated gradients or more than moderate PVL, occurring in 13%. The clinical efficacy endpoint after 30 days was observed in 37% of patients with the main contributor symptom worsening with New York Heart Association functional class III + in 17% of cases.
Conclusions
For the first time, VARC-2-defined composite endpoints at 1 year are reported and reveal a considerable proportion of patients experiencing the endpoint of time-related valve safety (29%) and clinical efficacy after 30 days (37%).